Brainstorm Cell Therapeutics (BCLI) Short Interest Ratio & Short Volume → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free BCLI Stock Alerts $0.56 -0.04 (-5.91%) (As of 03/28/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Brainstorm Cell Therapeutics Short Interest DataCurrent Short Volume850,300 sharesPrevious Short Volume1,070,000 sharesChange Vs. Previous Month-20.53%Dollar Volume Sold Short$283,064.87Short Interest Ratio / Days to Cover0.6Last Record DateMarch 15, 2024Outstanding Shares48,980,000 sharesPercentage of Shares Shorted1.74%Today's Trading Volume649,965 sharesAverage Trading Volume1,189,815 sharesToday's Volume Vs. Average55% Short Selling Brainstorm Cell Therapeutics ? Sign up to receive the latest short interest report for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatBCLI Short Interest Over TimeBCLI Days to Cover Over TimeBCLI Percentage of Float Shorted Over Time Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one Brainstorm Cell Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/2024850,300 shares $283,064.87 -20.5%N/A0.6 $0.33 2/29/20241,070,000 shares $392,690.00 -13.0%N/A0.7 $0.37 2/15/20241,230,000 shares $477,240.00 -39.4%N/A0.5 $0.39 1/31/20242,030,000 shares $717,199.00 -15.1%N/A0.8 $0.35 1/15/20242,390,000 shares $781,291.00 -43.2%N/A0.9 $0.33 12/31/20234,210,000 shares $1.15 million +25.3%N/A1.5 $0.27 Get the Latest News and Ratings for BCLI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/15/20233,360,000 shares $789,600.00 -4.0%N/A0.9 $0.24 11/30/20233,500,000 shares $976,500.00 -7.2%N/A1.1 $0.28 11/15/20233,770,000 shares $689,910.00 +5.6%N/A1.6 $0.18 10/31/20233,570,000 shares $546,210.00 -20.5%9.8%1.9 $0.15 10/15/20234,490,000 shares $763,300.00 +1.1%12.4%2.6 $0.17 9/30/20234,440,000 shares $888,444.00 +26.1%12.2%3 $0.20 9/15/20233,520,000 shares $3.39 million +9.3%9.7%9.3 $0.96 8/31/20233,220,000 shares $5.51 million +21.1%9.2%13.4 $1.71 8/15/20232,660,000 shares $4.15 million No Change7.6%11.3 $1.56 7/31/20232,660,000 shares $4.89 million -5.3%8.6%12 $1.84 7/15/20232,810,000 shares $5.54 million +0.4%9.1%12.1 $1.97 6/30/20232,800,000 shares $5.77 million +2.9%9.1%11.7 $2.06 6/15/20232,720,000 shares $7.37 million -5.6%8.8%6.7 $2.71 5/31/20232,880,000 shares $8.21 million +0.4%9.6%7.2 $2.85 5/15/20232,870,000 shares $7.92 million -9.2%9.5%8 $2.76 4/30/20233,160,000 shares $9.13 million +7.9%11.3%7.8 $2.89 4/15/20232,930,000 shares $8.23 million -5.5%10.4%7.3 $2.81 3/31/20233,100,000 shares $10.23 million +29.7%11.0%7.7 $3.30 3/15/20232,390,000 shares $3.87 million +0.8%8.5%10.2 $1.62 2/28/20232,370,000 shares $5.36 million +3.0%8.4%10.6 $2.26 2/15/20232,300,000 shares $5.24 million +18.6%8.1%9.6 $2.28 1/31/20231,940,000 shares $3.53 million -1.5%6.9%7 $1.82 1/15/20231,970,000 shares $2.88 million -3.9%7.0%8.3 $1.46 12/30/20222,050,000 shares $3.36 million -9.3%7.3%8.9 $1.64 12/15/20222,260,000 shares $4.09 million No Change8.0%9.6 $1.81 11/30/20222,260,000 shares $3.73 million -12.4%8.0%8.8 $1.65 11/15/20222,580,000 shares $4.46 million -4.1%9.1%9.8 $1.73 10/31/20222,690,000 shares $9.58 million +10.3%9.5%11.1 $3.56 10/15/20222,440,000 shares $8.49 million +23.2%8.7%10.2 $3.48 9/30/20221,980,000 shares $8.75 million +52.3%7.0%8.9 $4.42 9/15/20221,300,000 shares $5.59 million +68.2%4.6%7.2 $4.30 8/31/2022772,900 shares $2.80 million +36.6%2.7%5.3 $3.62 8/15/2022565,900 shares $1.95 million -5.4%2.0%4.8 $3.45 7/31/2022598,200 shares $1.53 million +3.1%2.1%9.8 $2.56Altcoin FRENZY Alert… (Ad)Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) BCLI Short Interest - Frequently Asked Questions What is Brainstorm Cell Therapeutics' current short interest? Short interest is the volume of Brainstorm Cell Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 15th, investors have sold 850,300 shares of BCLI short. Learn More on Brainstorm Cell Therapeutics' current short interest. What is a good short interest ratio for Brainstorm Cell Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BCLI shares currently have a short interest ratio of 1.0. Learn More on Brainstorm Cell Therapeutics's short interest ratio. Which institutional investors are shorting Brainstorm Cell Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Brainstorm Cell Therapeutics: Barclays PLC, Citadel Advisors LLC, ADAR1 Capital Management LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Brainstorm Cell Therapeutics' short interest increasing or decreasing? Brainstorm Cell Therapeutics saw a decrease in short interest in March. As of March 15th, there was short interest totaling 850,300 shares, a decrease of 20.5% from the previous total of 1,070,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Brainstorm Cell Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Brainstorm Cell Therapeutics: MiNK Therapeutics, Inc. (0.47%), Gamida Cell Ltd. (10.38%), Surrozen, Inc. (0.24%), Aptose Biosciences Inc. (0.54%), IN8bio, Inc. (0.29%), CASI Pharmaceuticals, Inc. (2.22%), Cyclo Therapeutics, Inc. (0.89%), OKYO Pharma Limited (0.28%), Pluri Inc. (0.52%), ZIVO Bioscience, Inc. (4.24%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Cummins Inc. ($8.93 billion), Canadian Natural Resources Limited ($7.79 billion), Super Micro Computer, Inc. ($4.31 billion), T-Mobile US, Inc. ($4.00 billion), General Motors ($3.36 billion), Occidental Petroleum Co. ($3.10 billion), Charter Communications, Inc. ($2.92 billion), Coinbase Global, Inc. ($2.74 billion), Tractor Supply ($2.72 billion), and Moderna, Inc. ($2.31 billion). View all of the most shorted stocks. What does it mean to sell short Brainstorm Cell Therapeutics stock? Short selling BCLI is an investing strategy that aims to generate trading profit from Brainstorm Cell Therapeutics as its price is falling. BCLI shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Brainstorm Cell Therapeutics? A short squeeze for Brainstorm Cell Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BCLI, which in turn drives the price of the stock up even further. How often is Brainstorm Cell Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BCLI, twice per month. The most recent reporting period available is March, 15 2024. More Short Interest Resources from MarketBeat Related Companies: MiNK Therapeutics Short Interest Data Gamida Cell Short Interest Data Surrozen Short Interest Data Aptose Biosciences Short Interest Data IN8bio Short Interest Data CASI Pharmaceuticals Short Interest Data Cyclo Therapeutics Short Interest Data OKYO Pharma Short Interest Data Pluri Short Interest Data ZIVO Bioscience Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BCLI) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaOnly a fool would buy Nvidia today… Porter & CompanyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory